학술논문
Development of morphea during Nivolumab treatment.
Document Type
Article
Author
Source
Subject
*NIVOLUMAB
*IMMUNE checkpoint inhibitors
*
Language
ISSN
0004-8380
Abstract
Immune-related adverse effects (IRAEs) are the most common type of immunotherapy toxicity and can affect any organ.1-3 CASE REPORT We present the case of a 72-year-old woman, with no relevant clinical history, who after a complete excision of a stage IV melanoma started adjuvant treatment with nivolumab. Targeted therapy and immunotherapy confer a longer life expectancy for patients with this disease. Keywords: immunotherapy; melanoma; nivolumab; scleroderma EN immunotherapy melanoma nivolumab scleroderma 269 271 3 05/20/22 20220501 NES 220501 INTRODUCTION Treatment for advanced melanoma has undergone a revolution. [Extracted from the article]